Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 352

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 352
---
 413,842

See accompanying notes.

F-4

PHATHOM PHARMACEUTICALS, INC. 

Statements of Operations and Comprehensive Loss 

(in thousands, except share and per share amounts)

    Years EndedDecember 31,

    2024

    2023

    Product revenue, net
     
    $
    55,252

    $
    682

    Cost of revenue

    7,973

    167

    Gross profit

    47,279

    515

    Operating expenses:

    Research and development

    34,082

    49,899

    Selling, general and administrative

    290,664

    117,928

    Total operating expenses

    324,746

    167,827

    Loss from operations

    (277,467
    )

    (167,312
    )

    Other (expense) income:

    Interest income

    15,158

    7,876

    Interest expense

    (72,009
    )

    (41,968
    )

    Other expense, net

    (8
    )

    (188
    )

    Total other expense

    (56,859
    )

    (34,280
    )

    Net loss and comprehensive loss
     
    $
    (334,326
    )
     
    $
    (201,592
    )

    Net loss per share, basic and diluted
     
    $
    (5.29
    )
     
    $
    (3.93
    )

    Weighted-average shares of common stock outstanding, basic and diluted

    63,176,210

    51,289,092

See accompanying notes

F-5

PHATHOM PHARMACEUTICALS, INC. 

Statements of Stockholders’ Deficit

(in thousands, except share amounts) 

    Common Stock

    Treasury Stock

    AdditionalPaid-in

    Accumulated

    TotalStockholders’

    Shares

    Amount

    Shares

    Capital

    Deficit

    Deficit

    Balance at December 31, 2023

    57,970,044

    $
    5

    19

    $
    855,921

    $
    (928,685
    )
     
    $
    (72,759
    )

    401(k) matching contribution